Wednesday, November 22, 2006 8:00:00 AM PDT | VentureDeal Staff
SAN DIEGO, CA -- Orexigen, a clinical-stage neuroscience company, announced the completion of its third round of funding in the amount of $30 million. New investors MPM BioEquities and Wasatch Advisors joined all existing investors in the new round.Orexigen, is developing two new drugs to treat obesity and is currently in phase II/III clinical testing. The company also has other drugs in earlier stages of testing.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
Founded in 2006, VentureDeal is a database that provides the latest information about venture capital firms, venture-backed technology companies and transactions throughout North America.
Learn More »
Email Sign Up
© 2014 VentureDeal, Inc., Menlo Park, CA. All Rights Reserved.